Posts by: Inês Martins, PhD

Inês Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

May 31, 2017May 31, 2017

FDA Grants Priority Review Status to Opdivo Application for Advanced Liver Cancer Patients

Liver cancer, News

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb seeking approval for Opdivo (nivolumab) to treat patients with ... Read more

May 24, 2017

Organovo’s 3D Bioprinted Tissue Transplants Improve Mice’s Liver Disease

News

Transplanting 3D bioprinted liver tissue into diseased livers improves liver health in mice, Organovo Holdings revealed. The finding suggests that doctors could use 3D bioprinted human liver tissue to correct inborn ... Read more

May 22, 2017May 22, 2017

Albireo Plans Phase 3 Trial of A4250 to Treat Children with Life-threatening Liver Disease

Cholestasis, News

Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability to combat the rare genetic disorder, according to its maker, ... Read more

May 15, 2017

Early Study to Test Bioelectronic Treatment for NASH Inflammation

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced. This is the first of multiple ... Read more

May 10, 2017May 10, 2017

Novartis Exercises Option to Develop and Market Conatus’ Emricasan to Treat NASH

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed in December 2016, Novartis will obtain the license ... Read more

May 9, 2017

First Patient Enrolled in Phase 2 Clinical Trial of Elafibranor for Bile Duct Disease

News, Non-alcoholic steatohepatitis

GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile duct disease known as primary biliary cholangitis (PBC). The study is recruiting ... Read more

May 5, 2017May 5, 2017

Can-Fite’s Namodenoson to Enter NAFLD/NASH Phase 2 Clinical Trial

Liver cancer, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will be conducted in two leading medical ... Read more

May 3, 2017May 12, 2017

Hepko-V5 Cancer Vaccine Boosts Survival Rates in Advanced Liver Cancer Patients, Mongolian Study Finds

Liver cancer, News

Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial. More than 90 percent of the ... Read more

March 23, 2017March 30, 2017

Thyroid, Kidney Cancer Drug Granted Orphan Drug Status for Hepatocellular Carcinoma

Liver cancer, News

The U.S. Food and Drug Administration has granted orphan drug status to cabozantinib for the treatment of hepatocellular carcinoma, the most common type of liver cancer. The designation is granted to ... Read more

March 3, 2017March 30, 2017

Breastfeeding Moms Who Consume Fructose May Increase Infant’s Risk of Metabolic Diseases, Including Fatty Liver

News, Non-alcoholic fatty liver disease

Consuming fructose, a sweetener used in processed foods and sodas, is an established risk factor for obesity and related metabolic diseases like Type 2 diabetes, cardiovascular disease, and non-alcoholic fatty ... Read more